{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:06:45Z","timestamp":1790046405400,"version":"4.0.1"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Immunocompromised patients account for about 3% of the US population. Complications arising from infection are common in these patients and can present diagnostic and therapeutic challenges. This article describes the pathophysiology of immunosuppression in five common immunocompromised states\u2014asplenia, HIV infection, solid organ transplant, biologic use, and cancer\u2014as well as specific infectious risks and considerations for affected patients and how to manage them.<\/jats:p>","DOI":"10.1097\/01.jaa.0000694948.01963.f4","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:11:38Z","timestamp":1597795898000},"page":"16-25","source":"Crossref","is-referenced-by-count":29,"title":["Infectious disease considerations in immunocompromised patients"],"prefix":"10.1097","volume":"33","author":[{"given":"Bridget","family":"McGrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Broadhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"23","key":"R1-20230817","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of immunosuppression among US adults, 2013","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"issue":"9785","key":"R2-20230817","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(10)61493-6","article-title":"Post-splenectomy and hyposplenic states","volume":"378","author":"Di Sabatino","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"R3-20230817","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMcp1314291","article-title":"Clinical practice. Care of the asplenic patient","volume":"371","author":"Rubin","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"R4-20230817","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nri1669","article-title":"Structure and function of the spleen","volume":"5","author":"Mebius","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"R5-20230817","first-page":"7","article-title":"Functional hyposplenism","volume":"18","author":"Kirkineska","year":"2014","journal-title":"Hippokratia"},{"issue":"12","key":"R6-20230817","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.ijsu.2014.11.005","article-title":"Overwhelming post splenectomy infection syndrome\u2014review study","volume":"12","author":"Sinwar","year":"2014","journal-title":"Int J Surg"},{"issue":"5","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijsu.2009.07.003","article-title":"Immunoprophylaxis in asplenic patients","volume":"7","author":"Harji","year":"2009","journal-title":"Int J Surg"},{"issue":"12","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"e1001194","DOI":"10.1371\/journal.pmed.1001194","article-title":"Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE","volume":"9","author":"Young","year":"2012","journal-title":"PLoS Med"},{"issue":"5","key":"R13-20230817","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"R14-20230817","first-page":"27","article-title":"Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men","volume":"72","author":"Maini","year":"1996","journal-title":"Genitourin Med"},{"key":"R15-20230817","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.med.60.041807.123549","article-title":"Emerging concepts in the immunopathogenesis of AIDS","volume":"60","author":"Douek","year":"2009","journal-title":"Annu Rev Med"},{"issue":"3","key":"R18-20230817","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1258\/0956462961917564","article-title":"Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS","volume":"7","author":"Miller","year":"1996","journal-title":"Int J STD AIDS"},{"issue":"1","key":"R19-20230817","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0891-5520(05)70292-0","article-title":"Fever in patients with HIV infection","volume":"10","author":"Sullivan","year":"1996","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"R20-20230817","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2796.1994.tb00840.x","article-title":"Fever of unknown origin in HIV-infected patients: a critical analysis of a retrospective series of 57 cases","volume":"236","author":"Bissuel","year":"1994","journal-title":"J Intern Med"},{"issue":"RR03","key":"R21-20230817","first-page":"1","article-title":"Revised surveillance case definition for HIV infection\u2014United States, 2014","volume":"63","author":"Selik","year":"2014","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"R22-20230817","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-100-5-663","article-title":"Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies","volume":"100","author":"Kovacs","year":"1984","journal-title":"Ann Intern Med"},{"issue":"24","key":"R23-20230817","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"R25-20230817","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M18-3600","article-title":"Recommended adult immunization schedule, United States, 2019","volume":"170","author":"Kim","year":"2019","journal-title":"Ann Intern Med"},{"issue":"26","key":"R27-20230817","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"R28-20230817","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.idc.2010.01.005","article-title":"Infection in organ transplantation: risk factors and evolving patterns of infection","volume":"24","author":"Fishman","year":"2010","journal-title":"Infect Dis Clin North Am"},{"issue":"25","key":"R29-20230817","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"R30-20230817","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajt.12093","article-title":"Introduction: infections in solid organ transplantation","volume":"13","author":"Green","year":"2013","journal-title":"Am J Transplant"},{"issue":"8","key":"R31-20230817","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R32-20230817","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jinf.2013.09.009","article-title":"BK and JC virus: a review","volume":"68","author":"Pinto","year":"2014","journal-title":"J Infect"},{"issue":"8","key":"R33-20230817","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/nep.12728","article-title":"BK virus nephropathy in renal transplant recipients","volume":"21","author":"Jamboti","year":"2016","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"R34-20230817","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"suppl 4","key":"R35-20230817","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"issue":"11","key":"R36-20230817","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R37-20230817","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol"},{"issue":"10","key":"R38-20230817","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"10","key":"R39-20230817","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/jir.2011.0065","article-title":"Cytokines in autoimmunity: role in induction, regulation, and treatment","volume":"31","author":"Moudgil","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"R40-20230817","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.idc.2010.01.006","article-title":"Infectious complications associated with immunomodulating biologic agents","volume":"24","author":"Koo","year":"2010","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"R41-20230817","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"R42-20230817","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"R43-20230817","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/ard.2011.152769","article-title":"Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Galloway","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"R44-20230817","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R45-20230817","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"R46-20230817","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"R47-20230817","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"R48-20230817","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"R49-20230817","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11926-013-0319-1","article-title":"Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV\/HCV","volume":"15","author":"Vassilopoulos","year":"2013","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"R50-20230817","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"12","key":"R51-20230817","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/acr.21784","article-title":"Management of Coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs","volume":"64","author":"Taroumian","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"R52-20230817","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"R53-20230817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"R54-20230817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"R55-20230817","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"R56-20230817","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"R58-20230817","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","article-title":"Prevention of infection due to Pneumocystis Spp. in human immunodeficiency virus-negative immunocompromised patients","volume":"17","author":"Rodriguez","year":"2004","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"R59-20230817","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.idc.2010.01.006","article-title":"Infectious complications associated with immunomodulating biologic agents","volume":"24","author":"Koo","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"R60-20230817","article-title":"SEER Cancer Statistics Review, 1975-2017","author":"Howlader"},{"issue":"6","key":"R61-20230817","first-page":"1","article-title":"Deaths: leading causes for 2017","volume":"68","author":"Heron","year":"2019","journal-title":"Natl Vital Stat Rep"},{"issue":"6","key":"R62-20230817","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"issue":"23","key":"R63-20230817","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"R64-20230817","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40121-017-0146-1","article-title":"Infections in cancer patients with solid tumors: a review","volume":"6","author":"Rolston","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"2","key":"R65-20230817","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"issue":"30","key":"R66-20230817","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"R67-20230817","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/21505594.2016.1141161","article-title":"Bloodstream infections in patients with solid tumors","volume":"7","author":"Gudiol","year":"2016","journal-title":"Virulence"},{"issue":"4","key":"R68-20230817","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R69-20230817","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1086\/383048","article-title":"Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens","volume":"39","author":"Ramphal","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R70-20230817","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/abr.abr_433_15","article-title":"Respiratory viruses in febrile neutropenic patients with respiratory symptoms","volume":"7","author":"Meidani","year":"2018","journal-title":"Adv Biomed Res"},{"issue":"suppl D","key":"R71-20230817","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/41.suppl_4.81","article-title":"Viral infections in neutropenia\u2014current problems and chemotherapeutic control","volume":"41","author":"Wood","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"R72-20230817","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"R73-20230817","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CLM.2006.n.049","article-title":"Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"7","author":"O'Brien","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"10","key":"R74-20230817","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"3","key":"R75-20230817","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"R76-20230817","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R78-20230817","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000694948.01963.f4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:21:36Z","timestamp":1692321696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000694948.01963.f4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000694948.01963.f4","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}